Apyx Medical Inc (APYX) 2025 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Ladies and gentlemen, good morning and welcome to the Apyx Medical first quarter 2025 earnings conference call. (Operator Instructions). As a reminder, this conference is being recorded.

    各位女士、先生,早安,歡迎參加 Apyx Medical 2025 年第一季財報電話會議。(接線員指示)。提醒各位,本次會議將被錄音。

  • It is now my pleasure to introduce your host, Jeremy Feffer from LifeSci Advisors. Please go ahead.

    現在我很榮幸介紹本次會議主持人:來自 LifeSci Advisors 的 Jeremy Feffer。請開始。

  • Jeremy Feffer - Investor Relations

    Jeremy Feffer - Investor Relations

  • Thank you and welcome everyone to our first quarter 2025 earnings call. Representing the company on the call are Charles Goodwin, Chief Executive Officer; and Matt Hill, Chief Financial Officer of Apyx.

    謝謝,並歡迎各位參加我們 2025 年第一季財報電話會議。代表公司出席本次電話會議的有:Apyx 執行長 Charles Goodwin,以及財務長 Matt Hill。

  • Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including without limitation those identified in the risk factor section of our most recent annual report on Form 10-K, our most recent 10-Q filing, and the company's other filings with the Securities and Exchange Commission.

    在開始之前,我想提醒各位,我們今天的發言以及對各位提問的回應可能包含前瞻性陳述,該等陳述係基於管理層目前的預期,並涉及固有風險與不確定性,可能導致實際結果與所示內容存在重大差異,包括但不限於我們最近一期 Form 10-K 年報、最近一期 10-Q 季報,以及公司向美國證券交易委員會提交之其他文件中的風險因素章節所識別者。

  • Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events, or otherwise. This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP financial measures.

    相關因素可能會不時在我們向 SEC 提交的文件中更新,並可於我們網站查閱。我們不承擔因新資訊、未來事件或其他原因而公開更新或修訂前瞻性陳述之任何義務。本次電話會議亦將提及若干未依一般公認會計原則(GAAP)計算之財務衡量指標。我們通常將其稱為非 GAAP 財務衡量指標。

  • Reconciliations of those non-gap financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the investor relations portion of our website.

    上述非 GAAP 財務衡量指標與依 GAAP 計算並呈列之最可比衡量指標之調節表,已刊載於我們網站投資人關係專區的財報新聞稿中。

  • I would now like to turn the call over to Mr. Charlie Goodwin, Apyx Medical's President and Chief Executive Officer. Please Go ahead.

    現在我想把電話會議交給 Apyx Medical 總裁兼執行長 Charlie Goodwin 先生。請開始。

  • Charles D Goodwin - President and Chief Executive Officer

    Charles D Goodwin - President and Chief Executive Officer

  • Thank you, Jeremy, and thank you all for joining us today. Per our usual format on these quarterly calls, I will be providing a review of our performance in the first quarter of 2025, and then I will turn the call over to Matt for a review of our first quarter financial results as well as our full year 2025 guidance. We will then open the call for your questions.

    謝謝你,Jeremy,也感謝各位今天加入我們。依照我們季度電話會議的一貫流程,我將先回顧 2025 年第一季的營運表現,接著把電話會議交給 Matt,請他回顧第一季財務結果以及我們 2025 全年指引。之後我們將開放提問。

  • Let me start with a review of our first quarter performance. We reported total revenue of $9.4 million for the quarter, a decrease of 8% compared to $10.2 million for the same period last year. While sales of our OEM products decreased as expected, sales of our advanced energy products increased 6% to $7.9 million for the first quarter of 2025 compared with last year's period. This reflects a building trend we have seen over the past year with stronger sales of single use handpieces in the United States.

    我先從第一季表現回顧開始。本季我們公布總營收為 940 萬美元,較去年同期的 1,020 萬美元下降 8%。雖然我們的 OEM 產品銷售如預期下滑,但先進能量產品銷售在 2025 年第一季成長 6% 至 790 萬美元,較去年同期增加。這反映出我們過去一年觀察到的趨勢:美國一次性使用手柄(single use handpieces)銷售更為強勁。

  • We also continue to see demand for capital equipment stabilize with increases year over year for two consecutive quarters in the US. We believe this speaks to the benefits offered by Renuvion as the only FDA cleared device for use after liposuction, as well as its ability to treat loose and lax skin. Digging further into our financial performance for the quarter, I want to point out that our team delivered these solid top line results, somewhat defying the industry.

    我們也持續看到資本設備需求趨於穩定,在美國已連續兩個季度呈現年增。我們認為,這凸顯了 Renuvion 作為唯一獲 FDA 核准可於抽脂後使用之裝置所提供的效益,以及其改善皮膚鬆弛與鬆垮的能力。進一步檢視本季財務表現,我想指出,我們團隊交出了穩健的營收表現,在某種程度上可說是逆勢而行。

  • We also implemented significant cost cutting measures and a restructuring program that right-sized our operations just six months ago. I think these initial results show this program is achieving its intended outcomes of reducing cost, reducing cash burn, and speaks to the dedication of our commercial strategy and vision for Apyx. Matt and I are very appreciative of everyone's effort, and I am truly excited about the direction we are heading.

    我們也在六個月前推動了大幅度的成本削減措施與重整計畫,使營運規模更貼近實際需求。我認為,這些初步成果顯示該計畫正達成其預期目標:降低成本、降低現金消耗,並展現我們對 Apyx 商業策略與願景的投入。Matt 和我非常感謝大家的努力,我也對我們前進的方向感到非常振奮。

  • We've laid a strong foundation that is energizing and setting the stage for meaningful growth, innovation, and impact. There are persistent macroeconomic headwinds impacting the global aesthetic space. At the same time, we believe the primary impact on the market is coming from the explosive growth of GLP-1. We estimate that over 15 million patients are currently using GLP-1 drugs, many of which we believe will seek treatment for loose and lax skin due to the associated rapid weight loss.

    我們已奠定堅實基礎,為有意義的成長、創新與影響力注入動能並鋪路。全球醫美市場仍面臨持續的總體經濟逆風。同時,我們認為市場的主要影響來自 GLP-1 的爆發式成長。我們估計目前有超過 1,500 萬名患者正在使用 GLP-1 藥物,其中許多人因快速減重而出現皮膚鬆弛與鬆垮,並可能尋求相關治療。

  • As I have mentioned previously, we are still in the early innings of this market when it comes to our role in serving these patients' needs as they meet their goal weight. In fact, Dr. Randy Boyet in her podcast cited a study of 1028 GLP-1 patients across 424 clinics examining the top 10 aesthetic treatments after medical weight loss. Number one was skin tightening treatments at 63%, and number 2 was body contouring fat reduction at 52%.

    如我先前提到的,就我們在協助這些患者於達到目標體重後滿足其需求而言,我們仍處於市場發展的早期階段。事實上,Randy Boyet 醫師在其 Podcast 中引用了一項研究,該研究涵蓋 424 家診所的 1,028 名 GLP-1 患者,檢視醫療減重後前 10 大醫美療程。排名第一的是皮膚緊緻療程,占 63%;排名第二的是身體雕塑/減脂療程,占 52%。

  • As the only true surgical aesthetics company, we believe we are uniquely positioned to take advantage of this burgeoning tailwind. This brings me to our renew on offering. We believe this minimally invasive surgical procedure is the best treatment option to address loose and lax skin, providing a durable and transformational result. It is our belief that Renuvion should be the standard of care for all patients, including those who have lost significant weight as a result of GLP-1 drugs.

    作為唯一真正的外科醫美公司,我們相信自己具備獨特優勢,能把握這股快速成長的順風。這也帶到我們的 Renuvion 方案。我們相信,這項微創外科療程是改善皮膚鬆弛與鬆垮的最佳治療選擇,可帶來持久且具轉變性的效果。我們認為,Renuvion 應成為所有患者的標準照護(standard of care),包括因使用 GLP-1 藥物而大幅減重的患者。

  • Our results are supported by long-term data. Just last month we announced the publication of two peer reviewed articles on two separate clinical studies that evaluated the use of Renuvion during body contouring procedures, including lipoabdominoplasty following significant weight loss. In these studies, the authors reported that patients in the Renovion group demonstrated improvements in abdominal skin laxity and excess skin, along with higher satisfaction scores.

    我們的成果亦有長期數據支持。就在上個月,我們宣布兩篇同儕審查文章發表,分別來自兩項獨立臨床研究,評估在身體雕塑手術中使用 Renuvion 的效果,包括在顯著減重後進行抽脂合併腹部整形(lipoabdominoplasty)。在這些研究中,作者指出 Renuvion 組患者在腹部皮膚鬆弛與多餘皮膚方面有所改善,且滿意度評分更高。

  • These papers highlight the use of Renouvion in combination with lift procedures, which are growing more than 20%. And please keep in mind that these newly published data simply reinforce a larger and growing body of evidence supporting the safety and utility of Renovion in aesthetic body contouring. For further validation, we are excited to announce just a few weeks ago that Renovion won the 2025 New Beauty Award for Best Minimally Invasive Skin tightener.

    這些論文凸顯了 Renuvion 與拉提手術合併使用的情境,而此類手術的成長率超過 20%。也請各位記得,這些新近發表的數據只是進一步強化一個更大且持續成長的證據體系,支持 Renuvion 在醫美身體雕塑中的安全性與實用性。為了進一步驗證,我們很高興宣布,就在幾週前,Renuvion 榮獲 2025 New Beauty Award「最佳微創皮膚緊緻療程」獎項。

  • As part of this process, new beauty editors tested thousands of products leading up to the 15th annual awards issue with a goal of selecting the most innovative beauty products, treatments, and trends. They also collaborate with board certified doctors and medical experts to determine the most effective results-driven in-office treatments and post-procedure essentials. And so, we are honored to have our game changing technology receive this accolade by such a trusted authority in the aesthetic space.

    在此評選過程中,New Beauty 編輯團隊在第 15 屆年度得獎專刊出刊前測試了數千項產品,目標是選出最具創新性的美容產品、療程與趨勢。他們也與具董事會認證的醫師及醫療專家合作,以評選最有效、以成果為導向的院內療程與術後必備品。因此,我們很榮幸這項具顛覆性的技術能獲得醫美領域如此值得信賴的權威所頒發的肯定。

  • Regarding our direct-to-consumer marketing strategy, our program continues to deliver outstanding results generating significant reach, views, and PR beyond our expectations. As I have mentioned previously, as part of this program, we have successfully leveraged several influencers who each bringing a unique voice and engaged audience to our campaign.

    關於我們的直接面向消費者(DTC)行銷策略,我們的計畫持續交出亮眼成果,帶來顯著的觸及、觀看數與公關聲量,超出我們的預期。如我先前提到,作為該計畫的一部分,我們已成功運用多位意見領袖(influencers),每位都為我們的活動帶來獨特的聲音與高度互動的受眾。

  • Most recently, we announced the appointment of Dolores Cantina as the chief of confidence for the brand's Renew You consumer marketing campaign, which exemplifies the brand's ability to reshape bodies and lives. As a beloved personality of the Real Housewives of New Jersey, Dolores provides a real take on the problem patients face with loose skin and the power of our body contouring technology.

    最近,我們宣布任命 Dolores Cantina 擔任品牌「Renew You」消費者行銷活動的信心長(Chief of Confidence),此活動展現了品牌重塑身形與人生的能力。作為《紐澤西嬌妻》(Real Housewives of New Jersey)中深受喜愛的人物,Dolores 以真實視角呈現患者面對皮膚鬆弛的困擾,以及我們身體雕塑技術的力量。

  • She is a powerful advocate for choosing board certified plastic or cosmetic surgeons for treatments and procedures. This overlaps really well with our messaging that Renovion is the number one trusted body contouring technology among these doctors along with clinical data, and we believe she will be a valuable member of the Apyx team.

    她強力倡議在接受治療與手術時,選擇具董事會認證的整形外科或醫學美容外科醫師。這與我們的訊息高度契合:Renovion 是這些醫師最信賴的第一名身體雕塑技術,並有臨床數據佐證;我們相信她將成為 Apyx 團隊的重要成員。

  • Turning to our development pipeline, we are very excited to have introduced our Aon body contouring on our third quarter call following the submission of the 5-K,10-K to the FDA in December. This all in one platform seamlessly integrates Renuvion, ultrasound assisted liposuction, power assisted liposuction, infiltration, Aspiration, electrocoagulization, and fat transfer into a single streamlined device.

    接著談到我們的研發產品線,在去年 12 月向 FDA 提交 5-K、10-K 之後,我們在第三季電話會議上介紹了 Aon 身體雕塑平台,對此我們感到非常振奮。這個一體化平台可無縫整合 Renuvion、超音波輔助抽脂、動力輔助抽脂、注入(infiltration)、抽吸(aspiration)、電凝(electrocoagulization)以及脂肪移植於單一精簡設備中。

  • Considering the major shifts in the market with rapid adoption of GLP-1, we believe AYON is a game changer for surgeons that will differentiate us and position Apyx as their surgical partner. Our goal for the next few years is to be able to walk into almost any surgeon's practice and see a on position in the heart of their operating room pending clearance. In late March, we offered an early look at AYON system to board certified plastic and cosmetic surgeons during the aesthetic meet in Austin, Texas, which is considered the premier event in aesthetics.

    考量到市場因 GLP-1 快速普及而出現重大轉變,我們相信 AYON 將成為外科醫師的遊戲規則改變者,能讓我們脫穎而出,並使 Apyx 成為他們的手術合作夥伴。我們未來幾年的目標是,在取得核准的前提下,幾乎走進任何外科醫師的診所,都能在其手術室核心位置看到 AYON。3 月下旬,我們在德州奧斯汀舉辦、被視為醫美領域頂級盛會的 aesthetic meet 期間,向具董事會認證的整形與醫學美容外科醫師提供 AYON 系統的搶先預覽。

  • I am excited to report that the feedback exceeded all expectations, as many of the physicians we spoke with confirmed that the AYON would be a welcome addition to many of their practices and provided for all of their surgical needs. Regarding timing, we are preparing for a planned launch of AYON in the back half of 2025 pending clearance.

    我很高興回報,回饋遠超出所有預期;我們交流的許多醫師都確認 AYON 將會是其多個診所的理想新增設備,並能滿足其所有手術需求。就時程而言,在取得核准的前提下,我們正準備於 2025 年下半年按計畫推出 AYON。

  • We expect the introduction of the AYON system to the market will help kickstart our equipment sales growth as we have an opportunity to capture new market share and expand our total addressable market in aesthetic surgery. I will now turn the call over to Matt for a review of our first quarter 2025 financial results in more detail along with our financial guidance for 2025.

    我們預期 AYON 系統導入市場將有助於啟動我們的設備銷售成長,因為我們有機會取得新的市占率,並在美學外科領域擴大我們的可服務總市場(TAM)。接下來我將把電話會議交給 Matt,請他更詳細回顧我們 2025 年第一季的財務結果,以及 2025 年的財務指引。

  • Matthew Hill - Chief Financial Officer

    Matthew Hill - Chief Financial Officer

  • Thanks, Charlie. Before I get started, please note that all references to first quarter financial results will be on a GAAP and year over year basis unless otherwise noted. As Charlie mentioned, total revenue for the first quarter 25% decreased 7.9% to $9.4 million compared to $10.2 million in the prior year period. Revenue for the advanced energy segment increased 5.8% to $7.9 million as a result of increased volume of single-use handpieces domestically, domestic and international sales of upgrades of the Apyx One console, and domestic sales of new generators.

    謝謝你,Charlie。在我開始之前,請注意:除非另有說明,所有第一季財務結果的提及皆以 GAAP 及年對年(YoY)為基礎。如 Charlie 所提到,2025 年第一季總營收較去年同期下降 7.9% 至 940 萬美元,去年同期為 1,020 萬美元。先進能量(advanced energy)部門營收成長 5.8% 至 790 萬美元,主要因國內一次性手把(single-use handpieces)出貨量增加、Apyx One 主機(console)升級在國內與國際的銷售,以及國內新發電機(generators)銷售所帶動。

  • These increases were partially offset by lower average selling price of generators to domestic customers and a general decrease in international sales. OEM segment sales decreased 44.7%, or approximately $1.2 million for the first quarter of '25 when compared to the first quarter of '24. The decrease in OEM sales was due to decrease in sales volume to existing customers, excluding symmetry surgical under our 10 year generator manufacturing and supply agreement.

    上述成長部分被以下因素抵銷:對國內客戶的發電機平均售價較低,以及國際銷售整體下滑。OEM 部門銷售在 2025 年第一季較 2024 年第一季下降 44.7%,約減少 120 萬美元。OEM 銷售下滑係因對既有客戶的銷售量下降(不含在我們 10 年期發電機製造與供應協議下的 Symmetry Surgical)。

  • Domestic revenue decreased 3.4% year over year to $6.7 million and international revenue decreased 17.7% year over year to $2.7 million. As a reminder, there's somewhat of a seasonality to the medical device business where quarterly revenue is normally the lowest in Q1 and Q3, and the highest in Q2 in Q4. Gross profit for the first quarter '25 decreased to $5.7 million compared with the $5.9 million in the prior year period.

    國內營收年對年下降 3.4% 至 670 萬美元,國際營收年對年下降 17.7% 至 270 萬美元。提醒一下,醫療器材業務具有一定季節性:季度營收通常在第一季與第三季最低,在第二季與第四季最高。2025 年第一季毛利降至 570 萬美元,去年同期為 590 萬美元。

  • Gross profit margin for the first quarter of '25 was 60.1% compared to 58.1% in the prior year period. The increase in gross profit margins was primarily attributable to the mix between our segments with advanced energy comprising a higher percentage of total sales and geographic mix within our advanced energy segment with domestic sales comprising a higher percentage of total sales. These increases were partially offset by a decrease in the average selling price of generators to domestic customers and product mix within our OEM segment.

    2025 年第一季毛利率為 60.1%,去年同期為 58.1%。毛利率提升主要歸因於部門組合:先進能量占總銷售比重提高;以及先進能量部門的地區組合:國內銷售占總銷售比重提高。上述提升部分被以下因素抵銷:對國內客戶的發電機平均售價下降,以及 OEM 部門的產品組合變化。

  • With respect to tariffs, we are actively monitoring trade policy and tariff announcements, including the recent executive orders issued by the US Federal Administration regarding tariffs on imports from various countries. At this time, the overall impact on our business related to these or any other tariffs that may be imposed remains uncertain and depends on multiple factors.

    關於關稅,我們正積極監控貿易政策與關稅公告,包括美國聯邦政府近期就對多國進口品關稅所發布的行政命令。目前,這些或未來可能實施的任何其他關稅對我們業務的整體影響仍不確定,並取決於多項因素。

  • Moving on to operating expenses, which decreased to $8.7 million for the first quarter '25 compared to $12.6 million in the prior year period. The decrease in operating expenses was driven by a $1.6 million dollar decrease in salaries and related costs, a $1.5 million dollar decrease in selling general administrative expenses, a $0.6 million dollar decrease in research and development expenses, and a $0.1 million dollar decrease in professional services expenses.

    接著看營業費用:2025 年第一季營業費用降至 870 萬美元,去年同期為 1,260 萬美元。營業費用下降主要由以下因素帶動:薪資及相關成本減少 160 萬美元、銷售與一般及行政費用減少 150 萬美元、研發費用減少 60 萬美元,以及專業服務費用減少 10 萬美元。

  • Loss from operations decreased $3.6 million or 54% to $3.1 million. Net loss attributable to the shareholders was $4.2 million or $0.10 per share for the first quarter '25 compared with $7.6 million of $0.22 per share in the prior year period. Adjusted to even a loss, decreased 54% to $2.4 million compared to $5.3 million in the first quarter of '24. As a reminder, we provide a detailed reconciliation from net loss attributable to stockholders to non-GAAP adjusted e loss in our earned press release.

    營業損失減少 360 萬美元(或 54%)至 310 萬美元。歸屬於股東的淨損為 420 萬美元(每股 0.10 美元),相較去年同期為 760 萬美元(每股 0.22 美元)。調整後 EBITDA 虧損下降 54% 至 240 萬美元,相較 2024 年第一季為 530 萬美元。提醒一下,我們在財報新聞稿中提供了從歸屬於股東的淨損到非 GAAP 調整後 EBITDA 虧損的詳細調節表。

  • For the three months ending March 31, 2025, cash used and operating activities decreased to $0.7 million compared to $6.3 million used in the prior year period. We were pleased with the cash and working capital management in the first quarter, and we expect to return to more normalized cash burden for the balance of '25. As of March 31, '25, the company had cash and cash equivalents of $31 million compared to $31.7 million as of December 31, '24. We believe based on our projections, including the uptake of the AYON platform, working capital management, and our strict cost controls, we will yield cash into 2027.

    截至 2025 年 3 月 31 日止三個月,營運活動使用的現金降至 70 萬美元,相較去年同期使用 630 萬美元。我們對第一季的現金與營運資金管理感到滿意,並預期在 2025 年其餘期間回到較正常的現金消耗水準。截至 2025 年 3 月 31 日,公司持有現金及約當現金 3,100 萬美元,相較 2024 年 12 月 31 日為 3,170 萬美元。我們相信,基於我們的預測(包括 AYON 平台的採用進展)、營運資金管理以及嚴格的成本控管,我們將可把現金續航延伸至 2027 年。

  • Turning to a review of our '25 guidance, which we reaffirmed in our first quarter '25 financial results press release issued earlier today for the 12 months ending December 31, 25, we expect total revenue in the range of $47.6 million to $49 million as compared to $48.1 million for the year ended December 31, 24. Our revenue guidance assumes advanced energy revenue in the range of $39.6 million to $41 million as compared to $38.6 million for the year ending December 31, '24.

    接著回顧我們 2025 年的指引:我們已在今日稍早發布的 2025 年第一季財務結果新聞稿中重申。就截至 2025 年 12 月 31 日止 12 個月而言,我們預期總營收介於 4,760 萬至 4,900 萬美元,相較截至 2024 年 12 月 31 日止年度為 4,810 萬美元。我們的營收指引假設先進能量營收介於 3,960 萬至 4,100 萬美元,相較截至 2024 年 12 月 31 日止年度為 3,860 萬美元。

  • OEM revenue is expected to come in at approximately $8 million as compared to $9.5 million for the year end in December 31, 24. We see Q2 OEM revenue to be similar to Q1, with the balance of the $8 million to be allocated to the back half of the year. We still anticipate gross margins of approximately 60% for the year and the total operating expenses not to exceed $40 million. This completes our prepared remarks. Charlie and I will now open the call for questions. Operator.

    OEM 營收預期約為 800 萬美元,相較於截至 2024 年 12 月 31 日年度的 950 萬美元。我們預期第二季 OEM 營收將與第一季相近,而 800 萬美元中的其餘部分將分配至下半年。我們仍預期全年毛利率約為 60%,且總營運費用不會超過 4,000 萬美元。以上為我們準備好的發言。接下來 Charlie 和我將開放提問。接線員。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Matt Hewitt, Craig Hallam Capital Group

    Matt Hewitt,Craig Hallam Capital Group

  • Matt Hewitt - Analyst

    Matt Hewitt - Analyst

  • Good morning. Thank you for taking the questions. Obviously, it's nice to hear that you're seeing some stability on the generator side. One of the opportunities with the AYON platform was that for the practices to obtain one of those they're going to have to kind of get in queue and to do that you were going to give priority to those that had upgraded to the Apyx one console. How is that progressing? Are you seeing customers enroll for that and what does the pipeline look on that side?

    早安。謝謝讓我提問。顯然,很高興聽到你們在發電機端看到一些穩定性。AYON 平台的一個機會在於,診所若要取得其中一台,就必須有點像排隊等候;而要做到這點,你們原本會優先提供給已升級至 Apyx One 主機台的客戶。目前進展如何?你們是否看到客戶為此而報名/加入?那邊的管線看起來如何?

  • Charles D Goodwin - President and Chief Executive Officer

    Charles D Goodwin - President and Chief Executive Officer

  • Yeah, thanks, Matt. I appreciate the question. Look, we're not going to comment on the pipeline for AYON yet. We're still waiting for clearance from the FDA and so we'll have plenty of time to update everybody on AYON and what's going on there. But obviously the announcement of a gives doctors and clinicians a huge impetus to upgrade to the Apyx one because of the excitement around AYON and so we're very happy with what we're seeing in the marketplace regarding that.

    好的,謝謝你,Matt。感謝這個問題。我們目前還不會評論 AYON 的管線。我們仍在等待 FDA 核准,因此之後會有充足時間向大家更新 AYON 以及相關進展。但顯然,相關公告確實給醫師與臨床人員很大的動力去升級到 Apyx One,因為大家對 AYON 感到興奮,所以我們對市場上看到的情況非常滿意。

  • Matt Hewitt - Analyst

    Matt Hewitt - Analyst

  • Yeah, I apologize. I could have been a little more clear. I was asking about the Apyx one console, the upgrades to just get in for AYON. I was just curious if you were seeing increased demand, for the Apyx one ahead of that.

    是的,抱歉。我剛才可以講得更清楚一些。我問的是 Apyx One 主機台,也就是為了排隊取得 AYON 而進行的升級。我只是好奇,在那之前你們是否看到 Apyx One 的需求增加。

  • Charles D Goodwin - President and Chief Executive Officer

    Charles D Goodwin - President and Chief Executive Officer

  • Yeah, no, that is actually what I tried to answer, and the answer to that is, we're happy with what we're seeing for that is the upgrade is people upgrading to the Apyx one and waiting for AYON.

    是的,沒錯,那其實就是我想回答的內容;答案是,我們對目前看到的情況感到滿意,也就是大家正在升級到 Apyx One,並等待 AYON。

  • Matt Hewitt - Analyst

    Matt Hewitt - Analyst

  • Got it. Alright and then as far as there was going to be a soft launch later this year I think last call you had kind of mentioned that you kind of had a list, but if you kind of solidified the list of practices that will. Receiving a on and are they getting set up kind of walk through the process once you do receive approval from the FDA what that that kind of first batch of KOLs. what that'll look like.

    了解。好,那另外關於今年稍晚會有一個軟性上市,我記得上次電話會議你們提到你們大概有一份名單,但不確定是否已經把將會收到 AYON 的診所名單定案。他們是否正在做準備?能否帶我們走一遍流程:一旦拿到 FDA 核准後,第一批 KOL(關鍵意見領袖)會是什麼樣子?

  • Charles D Goodwin - President and Chief Executive Officer

    Charles D Goodwin - President and Chief Executive Officer

  • Yeah, so we do, we have that list all solidified. We've got, 20 AYON ambassadors throughout the United States that are ready to go once we get clearance. Obviously, we would install the systems, get them and their staffs trained on everything, and then they would obviously start performing. In cases and give us feedback and all of that and that clock starts, when we get when we get clearance and then when you know we get everything installed and ready to go but we are making great progress with all of that and now it's just a matter of waiting.

    是的,我們已經把名單完全定案。我們在全美有 20 位 AYON 大使,等拿到核准就可以立即啟動。當然,我們會安裝系統,並訓練他們及其團隊熟悉所有內容,然後他們就會開始進行病例操作並提供回饋等等;這個時程會在我們取得核准後開始,接著在完成安裝並準備就緒後推進。不過我們在這些工作上進展非常順利,現在就只是等待而已。

  • Matt Hewitt - Analyst

    Matt Hewitt - Analyst

  • Understood. I mean one last one, and I know you touched on this a little bit in your prepared remarks, but obviously a friend of mine for a lot of investors recently has been tariffs, maybe just to remind everyone where you're obtaining your products from and what if anything would need to be done to mitigate any potential tariff impact. Thank you.

    了解。最後一題,我知道你們在準備好的發言中稍微提到過,但最近對許多投資人而言,一個「朋友」就是關稅;能否提醒大家你們的產品是從哪裡取得?以及若要降低任何潛在關稅影響,需要做哪些事情(如果需要的話)。謝謝。

  • Charles D Goodwin - President and Chief Executive Officer

    Charles D Goodwin - President and Chief Executive Officer

  • Yeah, no thanks, Matt. So, look, we get, we've got a supply chain where we get parts from all over the world, but one of the advantages that we have as a company is we have manufacturing both in the United States and we have manufacturing both in Sofia, Bulgaria. So based on what the environment is and what the best path for us, we can adjust manufacturing between the two facilities and so. We do have a little bit of flexibility when it comes to that.

    好的,謝謝你,Matt。我們的供應鏈會從世界各地取得零組件,但我們公司的一個優勢是,我們在美國有製造能力,同時也在保加利亞索菲亞有製造能力。因此,依據外部環境以及對我們最有利的路徑,我們可以在兩個廠區之間調整製造配置。所以在這方面我們確實有一些彈性。

  • Matt Hewitt - Analyst

    Matt Hewitt - Analyst

  • That's great thank you.

    太好了,謝謝。

  • Operator

    Operator

  • Sam Iberg, BTIG

    Sam Iberg,BTIG

  • Sam Iberg - Analyst

    Sam Iberg - Analyst

  • Hey, good morning, Charlie, Matt. Thanks for taking the questions here. Maybe I can just follow up on the last question on tariffs and obviously know there's a lot of moving parts here, but I guess as currently contemplated today, any way to size the impact, to margins at this point.

    嗨,早安,Charlie、Matt。謝謝讓我在這裡提問。我想跟進上一題關於關稅的問題;我知道這裡有很多變動因素,但就目前今天所設想的情況來看,是否有辦法估算對毛利率的影響幅度?

  • Charles D Goodwin - President and Chief Executive Officer

    Charles D Goodwin - President and Chief Executive Officer

  • So, if you, if Matt's prepared remarks, he talked that we're still expecting gross margins to be around 60% for the entire year. I think that's what we said at the beginning of the year and all of that would impact everything that we know right now based on the current situation.

    所以,如果你看 Matt 的準備發言,他提到我們仍預期全年毛利率約為 60%。我想這也是我們在年初所說的,而這已經把我們目前所知、基於現況的所有影響都納入考量。

  • Sam Iberg - Analyst

    Sam Iberg - Analyst

  • Okay, so sounds like pretty, minimal impact at this point. And then, maybe I can use my follow up here, on just how you're thinking about investments to support the AYON on launch. Obviously, I know you're keeping a close eye on cash burn and operating expenses, but how are you positioning, investments to support this launch while also, preserving capital here?

    好的,所以聽起來目前影響相當小。那我用追問來問一下,你們如何看待為支持 AYON 上市所需的投資。顯然我知道你們會密切關注現金消耗與營運費用,但你們如何在支持這次上市的同時,也能保留資本?

  • Charles D Goodwin - President and Chief Executive Officer

    Charles D Goodwin - President and Chief Executive Officer

  • Yeah, look, obviously expense control and cash management is incredibly important to us, but it's not at the expense of the AYON launch and everything that we've contemplated into our budget and the investments that we're making is there to support AYON and to be able to grow that and I remember we think that AYON is a huge differentiator for us at Apyx Medical and makes us a true partner for the surgeons, and we've got plans for how not only are we going to use capital to build new AYON.

    是的,你看,費用控管與現金管理對我們而言極其重要,但不會以犧牲 AYON 上市為代價。我們在預算中所規劃的一切,以及我們正在進行的投資,都是為了支持 AYON,並推動其成長。我們認為 AYON 對 Apyx Medical 來說是非常重要的差異化因素,也讓我們成為外科醫師真正的合作夥伴;而且我們也有計畫,不僅要如何運用資本來打造新的 AYON。

  • But obviously part of the social strategy to talk about that and everything else, so it's always been contemplated in there. We are going to do our best to keep managing expenses and managing our cash burn, but like I said, it won't be at the expense of the launch of AYON.

    當然也包括社群策略的一部分,用來溝通這件事以及其他所有事項,所以這些一直都已納入規劃。我們會盡最大努力持續管理費用並控制現金消耗,但如我所說,不會以犧牲 AYON 上市為代價。

  • Sam Iberg - Analyst

    Sam Iberg - Analyst

  • Okay, very good, thanks for taking the questions.

    好的,非常好,謝謝回答問題。

  • Operator

    Operator

  • If there are no further questions, please continue.

    若沒有其他問題,請繼續。

  • Charles D Goodwin - President and Chief Executive Officer

    Charles D Goodwin - President and Chief Executive Officer

  • Thank you, everyone.

    謝謝各位。

  • Operator

    Operator

  • Ladies and gentlemen, this concludes today's conference call.

    各位女士、先生,今天的電話會議到此結束。

  • Thank you for your participation. You may now disconnect.

    感謝各位的參與。您現在可以掛線。